Catalyst Pharmaceuticals Dividends and Buybacks
Dividend criteria checks 0/6
Catalyst Pharmaceuticals does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-5.5%
Buyback Yield
| Total Shareholder Yield | -5.5% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
We Ran A Stock Scan For Earnings Growth And Catalyst Pharmaceuticals (NASDAQ:CPRX) Passed With Ease
Dec 19
We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Profit Is Only A Baseline For What They Can Achieve
Nov 13Market Participants Recognise Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings
Nov 07Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)
Jul 24Catalyst Pharmaceuticals: New Products In Proving Phase
Jul 06Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)
Apr 06Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)
Jan 29Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk
Jan 17With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case
Sep 06Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?
May 27Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?
Feb 13Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?
Nov 11Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if CPRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CPRX's dividend payments have been increasing.
Dividend Yield vs Market
| Catalyst Pharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (CPRX) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Biotechs) | 2.5% |
| Analyst forecast (CPRX) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate CPRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CPRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate CPRX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CPRX has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/19 03:22 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Catalyst Pharmaceuticals, Inc. is covered by 19 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Charles Duncan | Cantor Fitzgerald & Co. |
| Samantha Lynn Semenkow | Citigroup Inc |